1. Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
   Xingcheng Yang et al, 2022, Hematological Oncology CrossRef
2. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
   Xiaomin Zhang et al, 2022, Frontiers in Immunology CrossRef
3. Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report
   Zhi-Yun Niu et al, 2021, World Journal of Clinical Cases CrossRef
4. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review
   Bibhu Prasad Satapathy et al, 2024, Frontiers in Immunology CrossRef
5. Prospects and challenges of CAR-T cell therapy combined with ICIs
   Yufan Lv et al, 2024, Frontiers in Oncology CrossRef
6. Comparison of Three CD3-Specific Separation Methods Leading to Labeled and Label-Free T Cells
   Ronald Weiss et al, 2021, Cells CrossRef
7. Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas
   null null et al, 2022, Aging Pathobiology and Therapeutics CrossRef